Leerink analysts noted, however, that Uplizna’s slow onset of therapeutic efficacy compares unfavorably to would-be ...

Inebilizumab, a first-in-class CD19+ B-cell–targeting agent, is safe and effective for up to 1 year in patients with generalized myasthenia gravis, a phase 3 trial suggests.

Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a ...

Amgen AMGN reported the latest data from the phase III MINT study that evaluated the rare disease drug Uplizna (inebilizumab) for label expansion in generalized myasthenia gravis (gMG) indication.

Myasthenia gravis is a rare neuromuscular disorder caused ... and rozanolixizumab (Rystiggo). Drugmaker Amgen expects to complete an FDA submission for inebilizumab in gMG in the first half ...

Amgen has shared new data from a late-stage trial of its B cell-depleting therapy Uplizna (inebilizumab-cdon) in adults with the rare autoimmune disorder generalised myasthenia gravis (gMG). The phase ...